Volume 19, Number 1—January 2013
Research
Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales
, Mary P.E. Slack, Nick J. Andrews, Pauline A. Waight, Ray Borrow, and Elizabeth Miller
Table 1
Characteristics of children with IPD in the cohort eligible for PCV7, England and Wales, September 4, 2006–March 31, 2010*
| Characteristic |
Age group, mo, no. (%)
|
Total, n = 1,332 | ||
|---|---|---|---|---|
| 3–11, n = 507 | 12–23, n = 446 | 24–59, n = 379 | ||
| Male sex | 307 (60.6) | 253 (56.7) | 220 (58.0) | 780 (58.6) |
| No comorbidity | 441 (87.0) | 392 (87.9) | 301 (79.4) | 1,134 (85.1) |
|
Any comorbidity
|
66 (13.0)
|
54 (12.1)
|
78 (20.6)
|
198 (14.9)
|
|
Serotype group |
||||
|
PCV7 |
95 (18.7) | 106 (23.8) | 47 (12.4) | 248 (18.6) |
|
Extra 3 PCV10 |
86 (17.0) | 78 (17.5) | 135 (35.6) | 299 (22.4) |
|
Extra 3 PCV13 |
134 (26.4) | 112 (25.1) | 90 (23.7) | 336 (25.2) |
|
Extra 11 PPV23 |
82 (16.2) | 62 (13.9) | 42 (11.1) | 186 (14.0) |
|
Other |
55 (10.8) | 39 (8.7) | 44 (11.6) | 138 (10.4) |
|
Not known |
55 (10.8)
|
49 (11.0)
|
21 (5.5)
|
125 (9.4)
|
| PCV7-IPD cases | ||||
|
Year 1 |
66/142 (46.5) | 88/136 (64.7) | 15/25 (60.0) | 169/303 (55.8) |
|
Year 2 |
17/104 (16.3) | 13/90 (14.4) | 13/69 (18.8) | 43/263 (16.3) |
|
Year 3 |
11/114 (9.6) | 4/116 (3.4) | 7/134 (5.2) | 22/364 (6.0) |
|
Year 4 (36–43 mo) |
1/92 (1.1)
|
1/55 (1.8)
|
12/130 (9.2)
|
14/277 (5.1)
|
| Comorbidity | ||||
|
Prematurity |
58 (11.4) | 44 (9.9) | 28 (7.4) | 130 (9.8) |
|
Septicemia |
272 (53.6) | 291 (65.2) | 209 (55.1) | 772 (58.0) |
|
Meningitis |
195 (38.4) | 70 (15.7) | 35 (9.2) | 300 (22.5) |
|
LRTI |
23 (4.5) | 82 (18.4) | 132 (34.8) | 237 (17.8) |
|
Other |
17 (3.4) | 3 (0.7) | 3 (0.8) | 23 (1.7) |
|
>1 PCV7 vaccine dose |
410 (80.9) | 315 (70.6) | 309 (81.5) | 1,034 (77.6) |
|
Hemolytic uremic syndrome† |
8 (1.6)
|
11 (2.5)
|
5 (1.3)
|
24 (1.8)
|
| Antimicrobial resistance | ||||
|
Penicillin‡ |
4/191 (2.1) | 5/154 (3.2) | 4/118 (3.4) | 13/465 (2.8) |
|
Erythromycin |
9/153 (5.9)
|
16/129 (12.4)
|
4/92 (4.3)
|
29/374 (7.8)
|
| Died and had | 27/507 (5.3) | 16/446 (3.6) | 15/379 (4.0) | 58/1,332 (4.4) |
|
No comorbidity |
17/437 (3.9) | 13/389 (3.3) | 10/295 (3.4) | 40/1,121 (3.6) |
|
Comorbidity |
10/70 (14.3) | 3/57 (5.3) | 5/84 (6.0) | 18/211 (8.5) |
|
Septicemia |
7/272 (2.6) | 5/291 (1.7) | 6/209 (2.9) | 18/772 (2.3) |
|
Meningitis |
18/195 (9.2) | 9/70 (12.9) | 6/35 (17.1) | 33/300 (11.0) |
|
LRTI |
1/23 (4.3) | 2/82 (2.4) | 3/132 (2.3) | 6/237 (2.5) |
|
Other |
1/17 (5.9) | 0/3 (0) | 0/3 (0) | 1/23 (4.3) |
|
Serotype group |
||||
|
PCV7 |
3/95 (3.2) | 6/106 (5.7) | 2/47 (4.3) | 11/248 (4.4) |
|
PCV10 |
3/86 (3.5) | 0/78 (0) | 2/135 (1.5) | 5/299 (1.7) |
|
PCV13 |
8/134 (6.0) | 3/112 (2.7) | 5/90 5.6) | 16/336 (4.8) |
|
PPV23 |
2/82 (2.4) | 5/62 (8.1) | 2/42 (4.8) | 9/186 (4.8) |
|
Other |
7/55 (12.7) | 0/39 (0) | 3/44 (6.8) | 10/138 (7.2) |
*IPD, invasive pneumococcal disease; PCV7, 7-valent pneumococcal conjugate vaccine, PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent polysaccharide vaccine; PCV7-IPD cases, IPD caused by the serotypes in PCV7; LRTI, lower respiratory tract infection.
†The responsible serotypes were 19A (13 cases, 52%), 7F (4 cases, 16%), 3 (3 cases, 12%), 1 (2 cases, 8%), 11A (1 case, 4%), and 22A (1 case, 4%).
‡Two isolates from each age group were of intermediate penicillin resistance.